Status and phase
Conditions
Treatments
About
The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 28 healthy subjects.
Subjects will receive famitinib malate on Day1 and Day13.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
28 participants in 2 patient groups
There are currently no registered sites for this trial.
Start date
May 11, 2022 • 2 years ago
End date
May 27, 2022 • 2 years ago
Today
Apr 04, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal